Blog – Page 5 – PRAIS 2.0

Home
Blog

FDA Approves Two Oral Therapies to Treat Gonorrhea

Murilo Freitas - 18:17, 11 de December de 202592

FDA Approves Two Oral Therapies to Treat Gonorrhea
http://www.fda.gov/news-events/press-announcements/fda-approves-two-oral-therapies-treat-gonorrhea

PAHO urges countries of the Americas to prioritize financial protection to advance towards universal health

admin - 20:28, 10 de December de 2025103

PAHO urges countries of the Americas to prioritize financial protection to advance towards universal health

Oscar Reyes

11 Dec 2025

FDA Proposes Expanding Sunscreen Active Ingredient List

Murilo Freitas - 13:20, 10 de December de 202583

FDA Proposes Expanding Sunscreen Active Ingredient List
http://www.fda.gov/news-events/press-announcements/fda-proposes-expanding-sunscreen-active-ingredient-list

PAHO supports Jamaica in the immediate deployment of mental health and psychosocial services after Hurricane Melissa

admin - 15:33, 9 de December de 2025116

PAHO supports Jamaica in the immediate deployment of mental health and psychosocial services after Hurricane Melissa

Cristina Mitchell

10 Dec 2025

Early Alert: Anesthesia System Issue from GE HealthCare

Murilo Freitas - 05:00, 9 de December de 2025278

GE HealthCare issues updated use instructions for certain Carestation 600 and 700 series Anesthesia Systems

http://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/early-alert-anesthesia-system-issue-ge-healthcare

MediNatura New Mexico, Inc. Issues Voluntary Nationwide Recall of ReBoost Nasal Spray Due to Microbial Contamination

Murilo Freitas - 05:00, 9 de December de 2025426

FOR IMMEDIATE RELEASE – December 10, 2025 – Albuquerque, New Mexico, MediNatura New Mexico, Inc. is voluntarily recalling one lot of ReBoost Nasal Spray to the consumer level. The product has been found to contain yeast/mold and microbial contamination with one species identified as Achromobacter, a

http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/medinatura-new-mexico-inc-issues-voluntary-nationwide-recall-reboost-nasal-spray-due-microbial

FDA Approves First Gene Therapy Treatment for Wiskott-Aldrich Syndrome

Murilo Freitas - 22:45, 8 de December de 2025210

FDA Approves First Gene Therapy Treatment for Wiskott-Aldrich Syndrome
http://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treatment-wiskott-aldrich-syndrome

First Approval in Commissioner’s National Priority Voucher Pilot Program Strengthens Domestic Antibiotic Manufacturing Capacity

Murilo Freitas - 21:28, 8 de December de 2025152

First Approval in Commissioner’s National Priority Voucher Pilot Program Strengthens Domestic Antibiotic Manufacturing Capacity

http://www.fda.gov/news-events/press-announcements/first-approval-commissioners-national-priority-voucher-pilot-program-strengthens-domestic-antibiotic

La OPS renueva el llamado a cerrar brechas de vacunación ante el resurgimiento de la tosferina en las Américas

admin - 14:34, 8 de December de 202588

PAHO renews call to close vaccination gaps amid whooping cough resurgence in the Americas

Cristina Mitchell

9 Dec 2025

FDA Approves First Cellular Therapy to Treat Patients with Severe Aplastic Anemia

Murilo Freitas - 18:02, 7 de December de 2025118

FDA Approves First Cellular Therapy to Treat Patients with Severe Aplastic Anemia
http://www.fda.gov/news-events/press-announcements/fda-approves-first-cellular-therapy-treat-patients-severe-aplastic-anemia

PRAIS 2.0